The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves' ophthalmopathy.
Sign Up to like & getrecommendations! Published in 2021 at "Experimental eye research"
DOI: 10.1016/j.exer.2021.108813
Abstract: BACKGROUND Orbital compartments harbor a variety of tissues that can be independently targeted in a plethora of disorders resulting in sight-threatening risks. Orbital inflammatory disorders (OID) including Graves' ophthalmopathy, sarcoidosis, IgG4 disease, granulomatosis with polyangiitis,… read more here.
Keywords: graves ophthalmopathy; inflammatory disorders; disease; including graves ... See more keywords
Clinical features and outcomes of IgG4-related idiopathic orbital inflammatory disease: from a large southern China-based cohort
Sign Up to like & getrecommendations! Published in 2020 at "Eye"
DOI: 10.1038/s41433-020-1083-x
Abstract: Purpose To investigate the clinical features and treatment outcomes of IgG4-related ophthalmic disease (IgG4-ROD) among idiopathic orbital inflammatory disease (IOID) patients. Methods The medical records of 165 biopsy-proven IOID patients were retrospectively reviewed. Biopsy specimens… read more here.
Keywords: idiopathic orbital; clinical features; disease; outcomes igg4 ... See more keywords
Disease modifying drugs in idiopathic sclerosing orbital inflammatory syndrome.
Sign Up to like & getrecommendations! Published in 2021 at "Orbit"
DOI: 10.1080/01676830.2021.1929338
Abstract: Purpose: Idiopathic sclerosing orbital inflammatory syndrome (ISOIS) is a rare, progressive and hard to control disease. There is a deep gap of evidence regarding application of disease-modifying drugs (DMD) regimen as a potentially effective treatment… read more here.
Keywords: sclerosing orbital; idiopathic sclerosing; inflammatory syndrome; disease ... See more keywords
Bilateral, sequential orbital inflammatory syndrome associated with ruxolitinib.
Sign Up to like & getrecommendations! Published in 2022 at "Orbit"
DOI: 10.1080/01676830.2022.2109177
Abstract: Ruxolitinib is an oral Janus associated kinase (JAK) inhibitor commonly used in the treatment of primary myelofibrosis. We describe a case of an 86-year-old woman on ruxolitinib for primary myelofibrosis who presented with a three-day… read more here.
Keywords: ruxolitinib; bilateral sequential; inflammatory syndrome; orbital inflammatory ... See more keywords